Home > Browse Issues > Vol.28 No.5
The Promoter Methylation Status of E-cadherin Gene in Plasma Cervical Cancer Patients
Chen-Chun Ren1,2, Xu-Hong Miao2, Bin Yang2, Lei Zhao2, Rui Sun2, Wen-Qin Song2*
1Department of Genetics, the Central Hospital of Gynecology and Obstetric, Tianjin 300052, China;2College of Life Sciences, Nankai University, Tianjin 300071, China
Abstract: Recent evidence suggests that tumor cells may release DNA into the serum and plasma of cancer patients and it can be used as a non-invasive marker for diagnosing cancer. In this study we examine the promoter methylation status of E-cadherin gene in 151 pretreatment plasma samples and 30 paired tumor tissue samples from cervical cancer patients using methylated specific polymerases chain reaction (MS-PCR). and sequencing. At the same time， chemical luminal immune assay (CLIA) was used to detect the squamous cell carcinoma (SCC) in plasma of cervical cancers. The results show that the sensitivity of the method is 40.39%， the specificity is 100% and the correct rate is 49.72%. The total concordant rate of methylation status between plasma samples and tissue samples was 76.67%. We could not find the methylation status in control groups. The higher of the clinical stage and histological grade is， the higher of the positive rate of methylation in E-cadherin gene in plasma samples. Compared with the results of SCC， MS-PCR is valuable in diagnosing cervical cancer in early stage and high grade. Using the E-cadherin gene as detecting marker we can diagnose and evaluate the effect of treatment to cervical cancers as soon as possible.
CN
EN